High response of second-line chemotherapy with pemetrexed or gemcitabine combined with carboplatin in patients with non-small-cell lung cancer experiencing progression following 6 months after concluding platinum-based chemotherapy

Medical Oncology

Volumn 28, Issue 1, 2011, Pages 300-306

  Arrieta, Oscar ^a,c   Villarreal Garza, Cynthia ^a   Pachuca, Digna ^a   Michel Ortega, Rosa M ^a   Martinez Barrera, Luis ^b   Flores Estrada, Diana ^a   Astorga, Alma ^a  

^a INSTITUTO NACIONAL DE CANCEROLOGÍA   (Mexico)

^b INSTITUTO NACIONAL DE ENFERMEDADES RESPIRATORIAS   (Mexico)

^c UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

Author keywords

Carboplatin; Gemcitabine; Non small cell lung cancer; Pemetrexed; Platinum; Second line chemotherapy

Indexed keywords

CARBOPLATIN; CISPLATIN; GEMCITABINE; PACLITAXEL; PEMETREXED; PLATINUM;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CLINICAL ARTICLE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HUMAN; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MALE; NAUSEA AND VOMITING; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; DEOXYCYTIDINE; DISEASE PROGRESSION; FEMALE; GLUTAMATES; GUANINE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME;

EID: 79952249569     PISSN: 13570560     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12032-009-9401-y     Document Type: Article

References (35)

1. DM Parkin F Bray J Ferlay P Pisani 2005 Global cancer statistics, 2002 CA Cancer J Clin 55 2 74 108 15761078 10.3322/canjclin.55.2.74 (Pubitemid 40372904)
2. JH Schiller, et al. 2002 Comparison of four chemotherapy regimens for advanced non-small cell lung cancer N Engl J Med 346 2 92 98 11784875 10.1056/NEJMoa011954 1:CAS:528:DC%2BD38Xkt1OlsQ%3D%3D (Pubitemid 34438899)
3. GV Scagliotti, et al. 2008 Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer J Clin Oncol 26 21 3543 3551 18506025 10.1200/JCO.2007.15.0375 1:CAS:528:DC%2BD1cXpvVWmtLg%3D
4. A Favaretto G Pasello C Magro C Schettino C Gridelli 2009 Second and third line treatment in non-small cell lung cancer Crit Rev Oncol Hematol 71 2 117 126 19249227 10.1016/j.critrevonc.2009.01.009
5. C Huisman EF Smit G Giaccone PE Postmus 2000 Second-line chemotherapy in relapsing and refractory non-small-cell-lung cancer: a review J Clin Oncol 18 3722 3730 11054445 1:CAS:528:DC%2BD3cXot1ant70%3D
6. FA Shepherd, et al. 2000 Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy J Clin Oncol 18 2095 2103 10811675 1:CAS:528:DC%2BD3cXktVyjsLc%3D (Pubitemid 30324363)
7. FV Fossella, et al. 2000 Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced NSCLC previously treated with platinum-containing regimens. The TAX 320 Non-Small-Cell Lung Cancer Study Group J Clin Oncol 18 2354 2362 10856094 1:CAS:528:DC%2BD3cXkvFWrsLg%3D (Pubitemid 30415821)
8. N Hanna, et al. 2004 Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy J Clin Oncol 22 1589 1597 15117980 10.1200/JCO.2004.08.163 1:CAS:528:DC%2BD2cXpsVWmurk%3D (Pubitemid 41079796)
9. FA Shepherd, et al. 2005 Erlotinib in previously treated non-small-cell lung cancer N Engl J Med 353 123 132 16014882 10.1056/NEJMoa050753 1:CAS:528:DC%2BD2MXmtFaksbo%3D (Pubitemid 41058344)
10. Groen H et al. The global TRUST study of erlotinib in advanced non-small-cell lung cancer (NSCLC). (Abstract). J Clin Oncol. 2008:26(20 suppl) abstr 19000 ASCO Annual Meeting.
11. RV Lord, et al. 2002 Low ERCC 1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer Clin Cancer Res 8 2286 2291 12114432 1:CAS:528:DC%2BD38XmtVWhsLw%3D (Pubitemid 34753602)
12. M Taron, et al. 2004 BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer Hum Mol Genet 13 2443 2449 15317748 10.1093/hmg/ddh260 1:CAS:528:DC%2BD2cXnvVOktLo%3D (Pubitemid 39377848)
13. Common Terminology Criteria for Adverse Events v3.0 (CTCAE). http://www.hovon.nl/upload/File/Studies-AlgStudInfo-HovonRichtlijnenDocs/ CTCAE-v3.0-12dec03.pdf Accessed May 24 2009. December 12, 2003.
14. Y Nakanishi, et al. 1999 Second-line chemotherapy with weekly cisplatin and irinotecan in patients with refractory lung cancer Am J Clin Oncol 22 399 402 10440199 10.1097/00000421-199908000-00016 1:STN:280:DyaK1Mzms1yisw%3D%3D (Pubitemid 30257642)
15. G Rosati A Rossi G Nicolella N Panza 2000 Second-line chemotherapy with paclitaxel, cisplatin and gemcitabine in pre-treated sensitive cisplatin-based patients with advanced non-small cell lung cancer Anticancer Res 20 3B 2229 2233 10928183 1:CAS:528:DC%2BD3cXlvFCqs7g%3D (Pubitemid 30636214)
16. S Kakolyris, et al. 2001 Cisplatin and irinotecan (CPT-11) as second-line treatment in patients with advanced non-small cell lung cancer Lung Cancer 34 Suppl 4 S71 S76 11742707 10.1016/S0169-5002(01)00384-1
17. M Oka, et al. 2001 Phase I study of second-line chemotherapy with docetaxel and carboplatin in advanced non-small-cell lung cancer Cancer Chemother Pharmacol 48 6 446 450 11800024 10.1007/s002800100369 1:CAS:528:DC%2BD3MXosFGnsbg%3D (Pubitemid 33139865)
18. E Laack, et al. 2002 Docetaxel and carboplatin as second-line chemotherapy for metastatic non-small cell lung cancer Lung Cancer 36 3 303 307 12009242 10.1016/S0169-5002(01)00477-9 (Pubitemid 34497131)
19. T Seto, et al. 2004 Doublet regimen of cisplatin plus docetaxel for second-line chemotherapy after prior therapy with cisplatin plus irinotecan for non-small cell lung cancer: a phase II study Int J Clin Oncol 9 5 378 382 15549588 10.1007/s10147-004-0422-4 1:CAS:528:DC%2BD2cXpt1ehsrk%3D (Pubitemid 40012706)
20. FM Wachters JW van Putten HM Boezen HJ Groen 2004 Phase II study of docetaxel and carboplatin as second-line treatment in NSCLC Lung Cancer 45 255 262 15246198 10.1016/j.lungcan.2004.02.006 (Pubitemid 38891489)
21. M Veslemes, et al. 2005 Phase II study of cisplatin-combined schedules as second-line chemotherapy in patients with non-small cell lung cancer Anticancer Res 25 4 2991 2996 16080557 1:CAS:528:DC%2BD2MXpt1WrtL4%3D (Pubitemid 41044692)
22. H Hamada, et al. 2007 Docetaxel and cisplatin as second-line chemotherapy for advanced non-small cell lung cancer Gan To Kagaku Ryoho 34 8 1235 1239 17687204 1:CAS:528:DC%2BD2sXhtVKlt7nJ
23. EF Smit, et al. 2009 Randomized phase II and pharmacogenetic study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non-small-cell lung cancer J Clin Oncol 12 2038 2045 10.1200/JCO.2008.19.1650
24. ME Van der Burg, et al. 1991 Carboplatin and cyclophosphamide salvage therapy for ovarian cancer patients relapsing after cisplatin combination chemotherapy Eur J Cancer 27 3 248 250 1827305 10.1016/0277-5379(91)90507-A
25. G Weiss, et al. 1991 Second-line treatment of advanced measurable ovarian cancer with iproplatin: a Southwest Oncology Group study Eur J Cancer 27 135 138 1827275 10.1016/0277-5379(91)90470-X 1:STN:280:DyaK3M3it1Kiug%3D%3D
26. M Markman, et al. 1991 Second line platinum therapy in patients with ovarian cancer previously treated with cisplatin J Clin Oncol 9 389 393 1999708 1:STN:280:DyaK3M7lsVyguw%3D%3D
27. F Zanaboni, et al. 1991 Salvage chemotherapy for ovarian cancer recurrence: weekly cisplatin in combination with epirubicin or etoposide Gynecol Oncol 43 24 28 1959783 10.1016/0090-8258(91)90004-O 1:STN:280: DyaK38%2FntVOgtQ%3D%3D
28. JT Thigpen RB Vance T Khansur 1993 Second line chemotherapy recurrent carcinoma of the ovary Cancer 71 4 suppl 1559 1564 8094320 1:STN:280: DyaK3s7mtFaqsg%3D%3D (Pubitemid 23056074)
29. M Markman MA Bookman 2000 Second line treatment of ovarian cancer Oncologist 5 26 35 10706647 10.1634/theoncologist.5-1-26 1:CAS:528: DC%2BD3cXitVeqtLs%3D (Pubitemid 30127542)
30. SM Tu E Hossan R Amato R Kilbourn CJ Logothetis 1995 Paclitaxel, cisplatin and methotrexate combination chemotherapy is active in the treatment of refractory urothelial malignancies J Urol 154 1719 1722 7563331 10.1016/S0022-5347(01)66765-X 1:STN:280:DyaK28%2FgvVequg%3D%3D
31. UN Vaishampayan, et al. 2005 Phase II trial of carboplatin and paclitaxel in cisplatin-pretreated advanced transitional cell carcinoma: a Southwest Oncology Group study Cancer 104 1627 1632 16138364 10.1002/cncr.21370 1:CAS:528:DC%2BD2MXhtF2nt73F (Pubitemid 41437425)
32. LC Pagliaro, et al. 2002 Cisplatin, gemcitabine, and ifosfamide as weekly therapy: a feasibility and phase II study of salvage treatment for advanced transitional-cell carcinoma J Clin Oncol 20 2965 2970 12089226 10.1200/JCO.2002.11.114 1:CAS:528:DC%2BD38Xlslyrt7s%3D (Pubitemid 34728891)
33. GP Stathopoulos SK Rigatos G Fountzilas A Polyzos JG Stathopoulos 2002 Paclitaxel and carboplatin in pretreated advanced gastric cancer: a phase II study Oncol Rep 9 89 92 11748462 1:CAS:528:DC%2BD38XmtVSitg%3D%3D
34. HM Chang, et al. 2005 Phase II study of paclitaxel and carboplatin in advanced gastric cancer previously treated with 5-fluorouracil and platinum Jpn J Clin Oncol 35 251 255 15886269 10.1093/jjco/hyi077 (Pubitemid 41444290)
35. KW Lee JH Kim T Yun, et al. 2007 Phase II study of low dose paclitaxel and cisplatin as a second-line therapy after 5-fluorouracil/platinum chemotherapy in gastric cancer J Korean Med Sci 22 suppl S115 S121 17923737 10.3346/jkms.2007.22.S.S115 1:CAS:528:DC%2BD2sXhsVektrfK